Nuveen’s DexCom DXCM Stock Holding History

Nuveen’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-26,800	Closed	-$2K	–	3206
2022 Q3	$2K	Buy	+26,800	New	+$2.27M	﹤0.01%	3256

Other funds holding DXCM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Nuveen's DXCM Position: Q2 2026 in Review

Nuveen increased its DexCom (DXCM) stake by 6.1% in Q2 2026, buying an estimated $7.05M and bringing the position to 1,830,235 shares worth $123M. The position accounts for 0.03% of the portfolio, ranked #366.

Nuveen first reported a position in DXCM in Q4 2013 and has held it in 48 quarters since. The position peaked at $1.15B in Q3 2021. 975 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

Nuveen held 1,830,235 shares of DexCom worth $123M as of Q2 2026.
Nuveen bought 105,768 DexCom shares in Q2 2026, an estimated $7.05M.
DexCom made up 0.03% of Nuveen's portfolio in Q2 2026, its #366 holding.
Nuveen first reported a position in DexCom in Q4 2013 and has held it in 48 quarters since.
Nuveen's DexCom position peaked at $1.15B in Q3 2021.
975 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.